Compare ATRC & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATRC | EYPT |
|---|---|---|
| Founded | 2000 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2005 | 2005 |
| Metric | ATRC | EYPT |
|---|---|---|
| Price | $41.22 | $16.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $52.00 | $29.60 |
| AVG Volume (30 Days) | 572.3K | ★ 1.1M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $518,304,999.00 | $42,339,000.00 |
| Revenue This Year | $16.90 | N/A |
| Revenue Next Year | $12.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 15.80 | N/A |
| 52 Week Low | $28.29 | $3.91 |
| 52 Week High | $43.11 | $19.11 |
| Indicator | ATRC | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 65.41 | 60.55 |
| Support Level | $38.92 | $15.97 |
| Resistance Level | $42.42 | $19.11 |
| Average True Range (ATR) | 1.66 | 0.95 |
| MACD | 0.56 | 0.04 |
| Stochastic Oscillator | 83.07 | 47.82 |
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.